🇺🇸 FDA
Patent

US 9957329

Factor XII inhibitors for the treatment of neurological inflammatory disorders

granted A61KA61K2039/505A61K38/06

Quick answer

US patent 9957329 (Factor XII inhibitors for the treatment of neurological inflammatory disorders) held by Julius-Maximilians-Universitat Wurzburg expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K38/06, A61K38/16, A61K38/1774